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Diﬀerential protein profiling of renal cell carcinoma
urinary exosomes†
F. Raimondo,za L. Morosi,za S. Corbetta,a C. Chinello,a P. Brambilla,a P. Della Mina,ab
A. Villa,ab G. Albo,c C. Battaglia,d S. Bosari,e F. Magnia and M. Pitto*a
Renal cell carcinoma (RCC) accounts for about 3% of all human malignancies and its incidence is
increasing. There are no standard biomarkers currently used in the clinical management of patients
with renal cell carcinoma. A promising strategy for new biomarker detection is comparative proteomics
of urinary exosomes (UE), nanovesicles released by every epithelial cell facing the urinary space,
enriched in renal proteins and excluding high-abundance plasmatic proteins, such as albumin. Aim of
the work is to establish the protein profile of exosomes isolated from urines of RCC patient compared
with control subjects. We enrolled 29 clear cell RCC patients and 23 control healthy subjects (CTRL), age
and sex-matched, for urine collection and vesicle isolation by diﬀerential centrifugation. Such vesicles
were morphologically and biochemically characterized and proved to share exosome properties.
Proteomic analysis, performed on 9 urinary exosome (UE) pooled samples by gel based digestion
followed by LC-MS/MS, led to the identification of 261 proteins from CTRL subject UE and 186 from
RCC patient UE, and demonstrated that most of the identified proteins are membrane associated or
cytoplasmic. Moreover, about a half of identified proteins are not shared between RCC and control UE.
Starting from these observations, and from the literature, we selected a panel of 10 proteins, whose UE
diﬀerential content was subjected to immunoblotting validation. Results show for the first time that
RCC UE protein content is substantially and reproducibly diﬀerent from control UE, and that these
diﬀerences may provide clues for new RCC biomarker discovery.
Introduction
Renal cell carcinoma (RCC), a human kidney cancer arising from
the proximal tubular epithelium, accounts for 2–3% of all malig-
nancies and is responsible for about 2% of all cancer deaths in
Western countries. Among RCC, the clear-cell type displays higher
frequency. Since small localized tumors rarely produce symptoms,
the diagnosis of RCC is often delayed until the disease is advanced.
Moreover, RCC is associated with a high potential of metastasis
and is resistant to both chemotherapy and radiotherapy, and
nephrectomy remains the most eﬀective treatment.1–3 Molecularly
targeted therapeutic options, mainly addressing products of the
VHL pathway, have recently been proven to provide clinical
benefits in phase III randomized clinical trials.4 Accordingly, many
RCC biomarker studies have selected components of the VHL
pathway for analysis, but despite these promising advances, treat-
ment decisions in RCC still depend on exclusively clinical criteria
and there are no standard biomarkers detectable in any biological
fluid currently used in the clinical management of patients with
renal cell carcinoma.5,6
Urine is an ideal biological sample for diagnosis of urologic
diseases, because of the ease and noninvasive nature of collection.
Moreover, it contains proteins of renal origin and may represent
the pathophysiological state of the kidney and the urologic tract.7
However, many abundant protein species found inside the urinary
proteome derive from plasma glomerular filtration. Urinary bio-
markers can be obtained from diﬀerent protein sources, including
soluble proteins, sediment proteins, and particle-bound proteins,
such as exosomes and microparticles.8
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Urinary exosomes are 30–100 nm vesicles coated with lipid
bilayer membranes, derived from all types of kidney cells
that contact the urinary space, including renal tubule cells.
Exosomes originate in multivesicular bodies (MVBs) and are
secreted into the extracellular fluid through fusion of MVBs
with the plasma membrane.9–11 The use of urinary exosomes as
a starting material for biomarker discovery was shown to be
advantageous, since reduction of the complexity of the urine
proteome together with enrichment in renal proteins towards
the plasmatic ones is achieved.12 In fact, exosome protein
content accounts for about 3% of the total proteins in normal
urine, and it is depleted from the most abundant ones, such as
albumin.13 Moreover, since exosomes from diﬀerent cell types
have diﬀerent components, it is likely that the exosome
proteome could better reflect, with respect to native urine,
the cellular processes associated with the pathogenesis of
RCC. In fact, it was suggested that urinary exosome excretion
may play a role in regulating renal epithelial protein content.14
Accordingly, several proteomic studies on urinary exosomes
have been performed to identify biomarkers predictive of
urinary track diseases, both in experimental and clinical
settings.7,13,15–18 For an exhaustive review see Moon et al.19
However no proteomic study of urinary exosomes has been yet
accomplished in RCC.
Therefore, we performed MS profiling and antibody-based
validation and quantification of diﬀerential proteins in urinary
exosomes from a RCC patient cohort in order to search for a
potential tumor marker.
Material and methods
Chemicals
Milli-Q water was used for all solutions. BCA protein assay,
trifluoroacetic acid, ammonium bicarbonate, porcine trypsin
DTT, iodoacetamide, Trizma-base, ACN, methanol, and CAPS
were from SIGMA Chemical Co. (St. Louis, MO, USA); glycerol
was from Merck (Darmstadt, Germany). Paraformaldehyde,
osmium tetroxide (OsO4), cacodylate buﬀer and LRW resin
were from Electron Microscopy Sciences (Hatfield, PA, USA).
The Hybond-ECL nitrocellulose membrane was from GE (Little
Chalfont, Buckinghamshire, UK). NuPAGEs SDS-PAGE Gel
Electrophoresis System components (mini gels, running and
loading buﬀers, molecular weight markers and Coomassie
blue staining) were supplied by Life Technologies (Paisley,
Renfrewshire, UK). An anti-protease inhibitor cocktail (Complete)
was from Roche (Monza, Italy). OptiPrepTM solution was from
Axis-Shield (Oslo, Norway). Themonoclonal anti-Flotillin 1 (Flot1)
antibody was purchased from Transduction Laboratories
(Lexington, KY, USA); the polyclonal anti-Dipeptidase1 (DPEP)
antibody from Genetex Inc. (Irvine, CA, USA); the polyclonal
anti-extracellular matrix metalloproteinase inducer (EMMPRIN/
CD147/Basigin) antibody from Zymed (San Francisco, USA);
the polyclonal anti-syntenin 1 (SDCBP) antibody from Abnova
(Taipei, Taiwan); the monoclonal anti-Aquaporin1 (AQP1)
antibody from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); monoclonal anti-tumor susceptibility gene 101 (TSG10),
anti-motility-related protein 1 (CD9), polyclonal anti-podocalixyn
(PODXL) and anti-neprilysin (CD10) antibodies from Abcam
(Cambridge, UK); polyclonal anti-dickkopf related protein 4
(DKK4) from Abgent (San Diego, CA, USA); monoclonal anti-
matrix metalloproteinase-9 (MMP9) from BD Bioscience
(San Jose´, CA, USA); monoclonal anti-carbonic anhydrase IX
(CAIX) is a kind gift from Dr Silvia Pastorekova (Slovak Academy
of Sciences, Bratislava, Slovak Republic). Species-specific
secondary peroxidase conjugated antibodies and ECL reagents
were from Pierce (Rockford, IL, USA).
Collection of human urine and normalization
Second morning urine samples (about 50 mL) were collected,
according to EuroKUP guidelines (http:www.eurokup.org) and
after the informed consent was approved by the Local Research
Ethics Committee, from 29 RCC patients (age 40–86, mean
63.5, 19 males and 10 females) before surgery, and 23 healthy
control subjects, matched for sex and age (age 50–78, mean,
59.2, 13 males and 10 females), and stored at 80 1C. The study
protocol, informed consent and procedures were approved by
the Local Research Ethics Committee of IRCCS Ca` Granda,
Ospedale Maggiore Policlinico and were in agreement with the
Declaration of Helsinki.
A brief description of the patients involved in this study is
shown in Table 1, and more detailed in Table S1 in ESI.† None
of the patients had received previous chemotherapy. RCC was
classified according to WHO recommendations20 also using
immunohistochemical techniques: only samples from diagnosed
conventional clear cell RCC (ccRCC) were included in the study.
Tumour staging and grading were assigned, according to the
2009 TNM (Tumor, Node, Metastasis) system classification, by a
pathologist.
An aliquot of the collected urine samples was subjected to
routine chemical–physical examination. Moreover, creatinine
assay (Jaﬀe´ method, Roche) was performed on individual urine
samples to normalize the gel loading of proteins to account for
diﬀerences in urine concentration.21
Purification of exosomes
Exosomes were prepared from each patient’s urine sample by
diﬀerential centrifugation22 and according to guidelines pro-
vided by EuroKUP (http:www.eurokup.org). Briefly, after sedi-
ment removal (10 min at 1000  g, 4 1C) and addition of
protease inhibitors (Complete, Roche), urine samples were
Table 1 Clinical characteristics of enrolled ccRCC patients
G pT Number of patients
1 2a 1
1a 5
2 1b 10
2a 6
2–3 1b 1
1a 1
1b 3
3 2a 1
2b 1
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centrifuged for 15 min at 17 000  g and 4 1C, to eliminate large
membrane fragments and debris. Supernatants were subjected
to ultracentrifugation for 1 h at 200 000  g and 4 1C: crude
exosome pellets were washed in PBS and then resuspended in
bidistilled water, in the presence of protease inhibitors. The
samples were stored at 80 1C until use.
In some cases, in order to verify the eﬃcacy of further
purification, the crude exosomes were subjected to OptiprepTM
density gradient ultracentrifugation.23 Briefly, the crude exo-
some pellet was overlaid on a discontinuous OptiPrep gradient
(40, 20, 10, and 5% OptiPrep solution in 0.25 M sucrose, 10 mM
Tris, pH 7.5) and centrifuged at 100 000  g for 16 h. Twelve
fractions (1 mL) were collected from the top of the gradient,
diluted with 2 mL of 10 mM Tris buﬀer, and centrifuged at
100 000  g for 3 h; after washing with PBS, the obtained pellets
were subjected to further analysis. The density of each fraction
was determined by absorbance at 244 nm using a duplicate
parallel discontinuous OptiPrep gradient overlaid with 500 mL
of 0.25 M sucrose, 10 mM Tris, pH 7.5.24
Moreover, we analyzed the protein composition of urine
samples after sediment removal (U), and of the supernatants
after 200 000  g ultracentrifugation (Sn).
In order to concentrate proteins, urine and Sn samples were
subjected to ultrafiltration: briefly, 500 mL of urine samples were
loaded onto concentrator devices, VivaSpin 500 (3000 MW cut-oﬀ
PES membrane, Sartorius), pre-treated with 5% Triton-X100 for
improved recovery of low-concentrated samples, according to the
manufacturer’s instruction. After a 45 min centrifugation at
15000  g (4 1C), the concentrate was collected and lyophilized.
Protein concentration was assessed by BCA assay (Sigma).
For protein identification and deglycosylation experiments,
representative UE derived from 9 RCC and 9 CTRL urine
samples were pooled and proteins separated by 4–12% gel
electrophoresis, followed by LC-MS/MS analysis.
Transmission electron microscopy
In order to validate exosome purity, Transmission Electron Micro-
scopy (TEM) imaging of exosomes was performed as below.
Briefly, after exosome purification, fresh exosomal preparations
were fixed with 4% paraformaldehyde and deposited on Formvar-
carbon-coated Nickel grids. Samples were post-fixed in 1% OsO4
in cacodylate buﬀer, dehydrated in ethanol and embedded in
LRW resin. Grids were doubly stained with uranyl acetate and lead
citrate and examined using a transmission electron microscope
CM 10 Philips (FEI, Eindhoven, the Netherlands).
Deglycosylation of exosome proteins
Removal of N- and O-linked glycans was performed using the
Glycoprotein Deglycosylation kit (Merck, Nottingham, UK)
according to the manufacturer’s instructions.25 Briefly, proteins
(15 mg) from pooled RCC and CTRL exosomes were dissolved in
reaction buﬀer (50 mM sodium phosphate buﬀer, pH 7.0) in
the presence of anti-proteases. Proteins were incubated with
denaturing solution (0.2% w/v SDS, 100mM b-mercaptoethanol),
at 100 1C for 5 minutes; then, Triton X-100 (0.75%) was added to
complex any free SDS. Enzymatic deglycosylation was carried out
by the addition of 1 mL of PNGase F (5000 U mL1), 1 mL of endo-
a-N-acetylgalactosaminidase (1.25 U mL1), 1 mL of a-2–3,6,8,9-
neuraminidase (5.0 U mL1), 1 mL of b-N-acetylglucosaminidase
(45 U mL1), and 1 mL of b-1,4-galactosidase (3.0 U mL1), and
samples were incubated overnight at 37 1C. Bovine fetuin was
deglycosylated under the same conditions, and used as a control.
Electrophoresis and western blotting
Equal amounts of exosome, urine and Sn proteins were sepa-
rated by 4–12% NuPAGE (Life technologies) and transferred to
nitrocellulose membranes, using a mini transfer tank (Hoefer).
After blocking with 5% free-fat milk/0.2% Tween 20 in PBS
solution, the blots were developed with the respective primary
antibodies followed by a peroxidase-conjugated secondary anti-
body (Pierce) and enhanced chemiluminescence detection
(SuperSignal West-Dura ECL, Pierce) by a CCD camera (Kodak
ds Image Station 2000 R). Densitometric analysis was performed
by molecular Imaging Software (Kodak) and the volumes of
band proteins were normalized to urinary creatinine content.14
Evaluation of diagnostic performance was accomplished by
ROC analysis (GraphPad Prism 5, GraphPad Software, Inc.).
For mass spectrometry analysis, pooled exosome proteins
were separated using a 4–12% NuPAGE electrophoresis system
(Life Technologies), and subjected to Coomassie Blue staining.
Mass spectrometry and protein identification
The bands of interest were excised from gels and subjected to
in-gel protein digestion as already described by Raimondo
et al.26 Briefly, the gel plugs were washed twice with a mixture
of 25 mM NH4HCO3–ACN (1 : 1; v/v) for 15 min. After 45 minute
reduction at 56 1C with 10 mM DTT, protein bands were
alkylated with 55 mM of IAA (dark; 30 min). Gel slices were
then washed again using ammonium bicarbonate, 25 mM, with
50% acetonitrile for three times. After dehydration with aceto-
nitrile, the proteins were in-gel digested with modified porcine
trypsin (Promega, Madison, WI, USA; 12.5 ng mL1 in 25 mM
NH4HCO3) at 37 1C overnight (8 mL for each sample). Digested
peptide solutions were then diluted in TFA 0.1% and the entire
volume was injected into nLC ESI MS/MS.
Protein identification was performed on a Proxeon EasynLC
System (Proxeon Biosystems, Odense, Denmark) coupled with a
MaXis hybrid UHR-QToF system (Bruker Daltonics, Bremen, DE).
After injection, trypsinized samples were thus desalted onto a
2 cm precolumn (ID 100 mm, 5 mm, C18–A1, EasycolumnTM,
Proxeon) and separated with a flow of 300 nL min1 on a 10 cm
fused silica micro-capillary analytical column (ID 75 mm, 3 mm,
C18–A2, EasycolumnTM, Proxeon) using a 60 min gradient
from 2 to 56% of acetonitrile containing 0.1% of formic acid
in 25 min and then from 56 to 98% in 10 min. The EasynLC
column was directly connected to the ESI source with a nano-
sprayer system (Bruker Daltonics, Bremen, DE). MS level mea-
surements were all performed on a predefined 50–2200 m/z
acquisition window at 1 Hz spectra rate. To improve mass
accuracy a specific lock mass (1221.9906 m/z) was used.
CID MS/MS acquisition was performed over a 400–1600 m/z
window (excluding 1221.5–1224 m/z) with five intensity binned
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precursors of preferred charge state range +2 to +4, with at least
2000 counts selected for fragmentation. Selected precursors
that had been analysed more than once were actively excluded
from analysis for 30 s. Isolation width and collision energy were
applied on the basis of isolation mass value and charge state
against a table of isolation and fragmentation lists fitted for
tryptic peptides. The total cycle time ranged from 6 to 11 seconds.
Ion transmission for MS–MS was also performed by setting key
parameters for the collision cell and the ion cooler cell as follows:
CCRF = 1200 Vpp and ICRF = 400 Vpp; transfer time ICTT =
100 ms and pre-pulse time ICPP = 8 ms.
Raw MS/MS data were lock-mass corrected, deconvoluted and
converted to an XML peaklist via Compass DataAnalysis v.4.0 Sp4
(BrukerDaltonics). Peakfinder (sumpeaks) was set to exclude any
ions with S/N o 1 and intensity o20 counts. In house Mascot
search engine (Version: 2.3.02) was used for processing XML
data. Database searching was restricted to the human Swissprot
(accessed Feb 2012; 20,317 sequences) database. Searches were
performed against the database using the following parameters:
fully tryptic enzymatic cleavage with one possible missed clea-
vage, a peptide tolerance of 10 ppm, and a fragment ion tolerance
of 0.5 Da. Fixed modification was set as carbamidomethyl due to
carboxyamidomethylation of cysteine residues. Mascot threshold
scores for identity were used as peptide level filters of peptide
significance. Protein identifications with a Mascot score above
the significant hit threshold (po 0.05) and at least one identical
peptide were considered significant.
Results and discussion
Urinary vesicle isolation and characterization
Urine samples were collected from 29 RCC patients and 23
healthy controls, matched for sex and age. The patients display
quite homogeneous clinical features, most of them were in early
phases of disease, with no metastasis nor positive lymph nodes
at the moment of diagnosis (Table 1; Tables S1 and S2 in ESI†).
All the patient and control subject urine samples were negative
for proteins, glucose, ketone, bilirubin, urobilinogen, and blood.
After urinary vesicle isolation, their protein concentration
was assessed, and referred to the initial urine volume (Tables S1
and S2 in ESI†). It is highly variable, as already reported,
ranging from 0.99 to 16 mg mL1 of starting urine samples in
patients, and from 2.78 to 11.8 mg mL1 in controls.27
In order to validate the exosome purification protocol, we
performed western blot analysis on the ultracentrifugation
pellets, in comparison with starting urine samples and the
ultracentrifugation supernatants (after suitable protein concen-
tration), using antibodies against three commonly used urinary
exosomal markers, CD9, TSG101 and Flotillin-1.28 Results show
that urinary exosome-associated protein signals were predomi-
nant in the vesicle fraction, and nearly undetectable in total
urine or the supernatant (Fig. 1A). Therefore markers are highly
and reproducibly enriched in the vesicle fraction, both in RCC
and in controls (Fig. 1B).
It has been reported29 that eﬃcient isolation and purification
of urinary exosomes facilitate quantitative and reproducible
proteomic investigation. However, this is obtained at the
expense of a very low recovery, and leads to the requirement
of huge amounts of starting material (as much as 1 L of urine
samples). This seems quite unsuited with the clinical needs.
Indeed, our results obtained by the application of a more
stringent isolation method (Optiprep gradient) show that exo-
some markers are mainly detectable in fraction 7, at a density
of 1.10 g mL1, as reported.30 However, it did not lead to a
substantially increased enrichment (Fig. S1 in the ESI†), com-
pared with an ultracentrifugation protocol (CE, crude exosomes),
while the yield was much lower.
Moreover, UE morphology, shape and dimension were
examined by electron microscopy, followed by morphometric
analysis. Vesicles are shown to have spherical shape and mean
diameter comprised between 30 and 50 nm, indicating that the
population of vesicles, prepared by UC, which we are dealing
with, is constituted mainly of real exosomes; in fact, the
spherical shape and the mean dimensions (Fig. 2 and 3) agree
with data present in the literature.30 Moreover, there are no
important morphological diﬀerences between exosomes in the
two groups (patients and controls), as shown also by the
morphometric analysis (Fig. 2A, B and 3).
Also in this case, when we further purified vesicles by the
Optiprep gradient, we did not observe any substantial change
in the vesicle appearance, except for the presence of a cleaner
background (Fig. S2 in the ESI†), confirming data regarding
marker enrichment. Accordingly, we concluded that the crude
preparations contain ‘‘bona fide’’ exosomes.
Electrophoresis analysis
In this study, the molecular weight distribution of UE proteins
was observed by NuPAGE, followed by Coomassie Blue staining.
As shown in Fig. 4, the distribution of protein bands following
gel electrophoresis was similar in starting urine and in the
supernatant after centrifugation at 200 000  g; instead, the
distribution of protein bands was diﬀerent in UE samples,
determining a typical protein profile: in fact albumin, respon-
sible for the main band appearance in the non-exosomal
fractions, results depleted, while THP, a glycoprotein released
by kidney tubular cells, is predominant in the UE profile,
Fig. 1 Urinary exosome protein markers. (A) Immunoblotting for known exo-
somal markers (CD9, TSG101 and Flot1) in vesicle fraction (Exo), in comparison
with total urine sample after sediment removal (U), and with the supernatant
(Sn), obtained after 200 000  g ultracentrifugation from a representative
control subject (CTRL). (B) Immunoblotting for the same markers in exosomal
samples from 3 representative CTRL subjects and RCC patients. Equal amounts of
proteins were loaded on all the lanes of each gel.
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although with diﬀerent intensity in the diﬀerent lanes (see
also Fig. 5). The variable content of THP may also explain
the variations encountered in total protein UE recovery
(see above).
Moreover, apart from THP, the exosomal protein composi-
tion was similar inside the same group (of RCC patients and
healthy controls), while it showed evident diﬀerences between
these two groups (Fig. 5). We also checked that the stability of
the similarity and the reproducibility of the diﬀerences were
independent of the time of collection (data not shown). There-
fore a consistent reproducibility is assured (Fig. 5).
Relying on this observation, we selected some representative
UE samples for pooling, aimed at proteomic analysis, before
and after enzymatic deglycosylation. Deglycosylation deter-
mined substantial changes in the UE protein profile, with an
evident shift of THP glycoprotein bands towards lower mole-
cular weights (Fig. S3 in ESI†).
Protein identification
In order to investigate the RCC and healthy control UE protein
profiles, we prepared a pool of UE from 9 diﬀerent patients and
another one from 9 healthy subjects. This allowed us to have
enough material and to reduce the eﬀect of interpersonal
variability. We identified 261 proteins in CTRL subjects’ UE
and 186 in RCC patients’ UE, some of which only after degly-
cosilation, likely due to the uncovering of some bands and the
Fig. 2 Morphological characterization of urinary exosomes. Electron micro-
graphs of crude exosomes doubly stained with uranyl acetate and lead citrate,
and examined by transmission electron microscope CM 10 Philips: (A) control UE;
(B) RCC UE.
Fig. 3 Size distribution (mean  SD) of urinary exosomes. A total of 15 fields
from two control subjects and two RCC patients were analyzed.
Fig. 4 Protein profiles by NuPAGE 4–12% of vesicle fraction (Exo), compared
with total urine samples after sediment removal (U), and with supernatant (Sn),
obtained after 200 000  g ultracentrifugation, from one representative control
subject (CTRL) and one RCC patient. Solid and dashed arrows indicate
the position of THP and albumin, respectively, both identified by MS (see ESI,†
Tables S3 and S4).
Fig. 5 Protein profiles by NuPAGE 4–12% of vesicle fraction (Exo), isolated from
urine samples of three representative control subjects and RCC patients.
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Table 2 List of proteins identified only in urinary exosomes isolated from control subject urine samples
Name Accession (UNIPROT) MW (Da) Mascot score Localization
Metabolic enzymes
1,5-Anhydro-D-fructose reductase Q96JD6 37 136 21 Cytoplasm
15-Hydroxyprostaglandin dehydrogenase [NAD+] P15428 29 187 59 Cytoplasm
3-Hydroxybutyrate dehydrogenase type 2 Q9BUT1 27 049 51 Cytoplasm
Alcohol dehydrogenase [NADP+] P14550 36 892 21 Other/unknown
Calpain-7 Q9Y6W3 93 335 40 Other/unknown
Carboxymethylenebutenolidase homolog Q96DG6 28 372 24 Cytoplasm
Dihydropteridine reductase P09417 26 001 31 Cytoplasm
Fidgetin-like protein 1 Q6PIW4 74 829 24 Other/unknown
Fructose-1,6-bisphosphatase 1 P09467 37 218 31 Cytoplasm
g-Butyrobetaine dioxygenase O75936 45 200 32 Cytoplasm
Glucose-6-phosphate isomerase P06744 63 335 36 Cytoplasm
Glutathione S-transferase A2 P09210 25 648 74 Cytoplasm
Glutathione S-transferase o-1 P78417 27 833 33 Cytoplasm
Glutathione S-transferase P P09211 23 569 32 Other/unknown
Glycerol-3-phosphate dehydrogenase [NAD+] P21695 38 171 27 Cytoplasm
Histone H2A type 1-A Q96QV6 45 087 82 Organelles
Maltase-glucoamylase O43451 211 031 94 Plasmamembrane
Non-secretory ribonuclease P10153 18 855 37 Organelles
Peroxiredoxin-1 Q06830 22 324 35 Cytoplasm
Protein S100-A6 P06703 59 899 97 Organelles
Pyruvate kinase isozymes M1/M2 P14618 58 470 60 Cytoplasm
Ribonuclease inhibitor P13489 51 766 28 Cytoplasm
Triosephosphate isomerase P60174 26 938 111 Other/unknown
Ubiquitin-conjugating enzyme E2 variant 3 Q8IX04 52 516 29 Other/unknown
Xaa-Pro dipeptidase P12955 55 311 25 Plasmamembrane
Signalling
14-3-3 Protein e P31946 29 326 56 Cytoplasm
14-3-3 Protein z/d P63104 27 899 74 Cytoplasm
ADP-ribosyl cyclase 2 Q10588 36 328 44 Plasmamembrane
Annexin A4 P09525 36 088 340 Cytoplasm
Calbindin P05937 30 291 46 Cytoplasm
Cofilin-1 P23528 18 719 45 Cytoplasm
G-protein coupled receptor family C group 5 member B Q9NZH0 45 279 140 Plasmamembrane
G-protein coupled receptor family C group 5 member C Q9NQ84 48 732 103 Plasmamembrane
G-protein G(I) subunit a-2 P04899 40 995 86 Plasmamembrane
G-protein G(I)/G(S)/G(T) subunit b-2 P62879 38 048 69 Plasmamembrane
G-protein subunit a-13 Q14344 44 364 48 Plasmamembrane
Neprilysin P08473 86 144 151 Plasmamembrane
Programmed cell death protein 10 Q9BUL8 24 686 34 Plasmamembrane
Proto-oncogene tyrosine-protein kinase Src P12931 60 310 33 Plasmamembrane
Ras-related C3 botulinum toxin substrate 2 P15153 21 814 36 Cytoplasm
Ras-related protein Ral-B P11234 23 508 53 Plasmamembrane
Ras-related protein Rap-1A P62834 21 316 63 Plasmamembrane
Ras-related protein R-Ras2 P62070 23 613 42 Plasmamembrane
Rho guanine nucleotide exchange factor 10-like protein Q9HCE6 141 873 26 Cytoplasm
Tetraspanin-1 O60635 26 910 68 Plasmamembrane
Transforming protein RhoA P61586 22 096 26 Plasmamembrane
Vesicular traﬃcking
14 225 Q9H1C7 11 488 36 Plasmamembrane
ADP-ribosylation factor 6 P62330 20 183 62 Organelles
Annexin A1 P04083 38 918 105 Plasmamembrane
Annexin A7 P20073 52 991 108 Secreted
Charged multivesicular body protein 1b Q7LBR1 22 152 112 Organelles
Charged multivesicular body protein 2a O43633 25 088 81 Organelles
Charged multivesicular body protein 4b Q9H444 24 935 148 Organelles
Charged multivesicular body protein 5 Q9NZZ3 24 612 51 Organelles
Copine-3 O75131 60 947 68 Cytoplasm
Copine-8 Q86YQ8 63 638 34 Other/unknown
EH domain-containing protein 1 Q9H4M9 60 646 84 Plasmamembrane
EH domain-containing protein 4 Q9H223 61 365 107 Plasmamembrane
Lysosome-associated membrane glycoprotein 1 P11279 45 367 75 Organelles
Multivesicular body subunit 12A Q96EY5 29 107 56 Organelles
Ras-related protein Rab-10 P61026 22 755 92 Plasmamembrane
Ras-related protein Rab-11A P62491 24 492 71 Plasmamembrane
Ras-related protein Rab-11B Q15907 24 588 53 Plasmamembrane
Ras-related protein Rab-2A P61019 23 702 36 Organelles
Ras-related protein Rab-3A P20336 25 196 53 Plasmamembrane
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Table 2 (continued )
Name Accession (UNIPROT) MW (Da) Mascot score Localization
Ras-related protein Rab-5B P61020 23 920 47 Plasmamembrane
Ras-related protein Rab-8B Q92930 23 740 45 Plasmamembrane
Vacuolar protein sorting-associated protein 28 Q9UK41 25 694 65 Plasmamembrane
Vacuolar protein sorting-associated protein 37D Q86XT2 27 941 82 Organelles
Vacuolar protein sorting-associated protein 4A Q9UN37 49 152 77 Organelles
Vacuolar protein sorting-associated protein VTA1 homolog Q9NP79 34 143 39 Organelles
WASH complex subunit strumpellin Q12768 135 113 34 Organelles
Transport
Aquaporin-2 P41181 29 047 45 Plasmamembrane
Chloride intracellular channel protein 4 Q9Y696 28 982 31 Plasmamembrane
Cytochrome b reductase 1 Q53TN4 31 735 32 Plasmamembrane
Electrogenic sodium bicarbonate cotransporter 1 Q9Y6R1 122 295 25 Plasmamembrane
MIT domain-containing protein 1 Q8WV92 29 638 67 Organelles
Multidrug resistance protein 1 P08183 141 788 65 Plasmamembrane
Na(+)/H(+) exchange regulatory cofactor NHE-RF3 Q5T2W1 57 379 21 Plasmamembrane
Protein MAL2 Q969L2 19 341 51 Plasmamembrane
Proton-coupled amino acid transporter 2 Q495M3 53 809 37 Plasmamembrane
Ras-related protein Rab-1A P62820 22 891 78 Organelles
Retinol-binding protein 5 P82980 16 092 39 Cytoplasm
Selenium-binding protein 1 Q13228 52 928 43 Cytoplasm
Solute carrier family 12 member 3 P55017 114 193 70 Plasmamembrane
Solute carrier family 22 member 2 O15244 63 265 30 Plasmamembrane
Solute carrier family 23 member 1 Q9UHI7 65 644 27 Plasmamembrane
V-type proton ATPase subunit B, brain isoform P21281 56 807 24 Organelles
V-type proton ATPase subunit B, kidney isoform P15313 57 196 26 Organelles
V-type proton ATPase subunit C 1 P21283 44 085 21 Organelles
Adhesion/cytoskeleton
Galectin-3 P17931 26 193 27 Cytoplasm
Insulin-like growth factor-binding protein 7 Q16270 30 138 28 Secreted
Actin-related protein 2/3 complex subunit 2 O15144 34 426 37 Cytoskeleton
Annexin A11 P50995 54 697 655 Cytoskeleton
Brain-specific angiogenesis inhibitor 1-associated protein 2 Q9UQB8 61 115 40 Cytoplasm
Desmoplakin P15924 334 021 29 Cytoskeleton
Kinesin-like protein KIF12 Q96FN5 71 813 29 Cytoskeleton
Macrophage-capping protein P40121 38 779 32 Cytoplasm
Myosin-1c O00159 122 503 156 Cytoplasm
Nck-associated protein 1 Q9Y2A7 130 018 48 Organelles
Nesprin-1 Q8NF91 1 017 069 18 Cytoskeleton
Perlecan P98160 479 221 29 Secreted
Profilin-1 P07737 15 216 30 Cytoskeleton
Putative b-actin-like protein 3 Q9BYX7 42 331 42 Cytoskeleton
Radixin P35241 68 635 100 Plasmamembrane
Uroplakin-2 O00526 103 846 32 Cytoskeleton
WD repeat-containing protein 1 O75083 66 836 23 Cytoplasm
Immune response
Thioredoxin P10599 77 224 116 Secreted
Toll-interacting protein Q9H0E2 30 490 78 Cytoplasm
Xaa-Pro aminopeptidase 2 O43895 76 090 32 Plasmamembrane
Others/unknowns
CD2-associated protein Q9Y5K6 71 635 43 Cytoskeleton
Ankyrin repeat and FYVE domain-containing protein 1 Q9P2R3 129 915 69 Organelles
Annexin A6 P08133 76 168 97 Cytoplasm
Azurocidin P20160 27 325 26 Cytoplasm
Brain acid soluble protein 1 P80723 22 680 116 Plasmamembrane
Brevican core protein Q96GW7 100 539 22 Secreted
Centrosomal protein of 290 kDa O15078 290 892 27 Cytoplasm
Chromobox protein homolog 2 Q14781 56 388 21 Other/unknown
Coiled-coil and C2 domain-containing protein 1A Q6P1N0 104 397 45 Cytoplasm
Cullin-associated NEDD8-dissociated protein 1 Q86VP6 137 999 36 Other/unknown
DNA excision repair protein ERCC-6 Q03468 169 452 27 Other/unknown
Elongation factor 1-a 1 P68104 50 451 53 Cytoplasm
Heat shock 70 kDa protein 1-like P34931 70 730 44 Cytoplasm
Histone H3.1t Q16695 14 225 26 Other/unknown
Histone H4 P62805 10 966 86 Other/unknown
Hsc70-interacting protein P50502 41 477 72 Cytoplasm
Lysosomal protective protein P10619 54 944 59 Organelles
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Table 2 (continued )
Name Accession (UNIPROT) MW (Da) Mascot score Localization
Myeloperoxidase P05164 84 784 61 Organelles
PDZK1-interacting protein 1 Q13113 12 333 51 Plasmamembrane
Peflin Q9UBV8 30 646 46 Cytoplasm
Phosphatidylethanolamine-binding protein 1 P30086 21 158 108 Cytoplasm
Proactivator polypeptide P07602 11 360 111 Other/unknown
Probable Xaa-Pro aminopeptidase 3 Q9NQH7 57 624 25 Organelles
Prolactin-inducible protein P12273 16 847 33 Secreted
Protein S100-A9 P06702 13 291 82 Cytoplasm
Semenogelin-1 P04279 52 157 44 Secreted
Semenogelin-2 Q02383 65 519 27 Secreted
THAP domain-containing protein 4 Q8WY91 63 535 23 Other/unknown
Transmembrane protease serine 2 O15393 55 079 39 Plasmamembrane
Transmembrane protein C19orf77 O75264 15 012 53 Plasmamembrane
Tubulin polyglutamylase TTLL7 Q6ZT98 12 015 83 Cytoplasm
Tyrosine-protein kinase FRK P42685 58 673 35 Cytoplasm
Uroplakin-1a O00322 29 429 32 Plasmamembrane
Vesicle-associated membrane protein 8 Q9BV40 19 540 83 Plasmamembrane
Vitamin K-dependent protein Z P22891 46 026 26 Secreted
Mascot score = Mascot threshold scores for identity were used as peptide level filters of peptide significance. Protein identifications with a Mascot
score above the significant hit threshold (p o 0.05) and at least one identical peptide were considered significant. Localization = subcellular
localization based on UniProtKB.
Table 3 List of proteins identified only in urinary exosomes isolated from RCC patient urine samples
Name Accession (UNIPROT) MW (Da) Mascot score Localization
Metabolic enzymes
1-Acyl-sn-glycerol-3-phosphate acyltransferase a Q99943 32 038 32 Plasmamembrane
6-Phosphogluconolactonase O95336 27 815 123 Organelles
Abhydrolase domain-containing protein 14B Q96IU4 22 446 47 Organelles
Aspartate aminotransferase P17174 46 447 23 Organelles
Bile salt-activated lipase P19835 79 614 29 Secreted
Carbonic anhydrase 1 P00915 28 909 21 Organelles
Dipeptidyl peptidase 2 Q9UHL4 54 763 19 Organelles
Lysosomal acid phosphatase P11117 48 713 115 Organelles
N-Acetylgalactosamine-6-sulfatase P34059 58 445 26 Organelles
Pepsin A P00790 42 350 43 Secreted
Peroxiredoxin-2 Q06830 22 049 46 Organelles
Phosphoglycerate kinase 1 P00558 44 985 28 Organelles
Prostate-specific antigen P07288 29 293 27 Secreted
Tissue a-L-fucosidase PO4066 53 940 25 Organelles
Signalling
Angiotensinogen P01019 53 406 22 Secreted
Chondroitin sulfate proteoglycan 4 Q6UVK1 251 067 95 Plasmamembrane
Dapper homolog 1 Q9NYF0 91 145 31 Cytoplasm
Dickkopf-related protein 4 Q9UBT3 26 057 14 Secreted
G-protein G(S) subunit a isoforms XLas Q5JWF2 79 Plasmamembrane
Ras-related C3 botulinum toxin substrate 1 P63000 21 835 25 Plasmamembrane
Vasorin Q6EMK4 72 751 72 Plasmamembrane
Vesicular traﬃcking
Ras-related protein Rab-1A P62820 22 891 66 Organelles
Transport
Apolipoprotein A-I P02647 30 759 71 Secreted
Ceruloplasmin P00450 122 983 274 Secreted
Cytochrome b561 P49447 27 713 24 Plasmamembrane
Hemoglobin subunit b P68871 16 102 72 Other/unknown
Nuclear transport factor 2 P61970 14 640 34 Cytoplasm
Receptor activity-modifying protein 2 O60895 19 880 21 Plasmamembrane
Serotransferrin P02787 79 280 349 Secreted
Thyroxine-binding globulin P05543 46 637 21 Secreted
Transthyretin P02766 15 991 48 Secreted
Adhesion (cytoskeleton)
Actin-related protein 2/3 complex subunit 4 P59998 19 768 27 Cytoskeleton
Collagen a-3(VI) chain P12111 345 167 44 Secreted
F-actin-capping protein subunit a-1 P52907 33 073 51 Cytoplasm
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sharpening of others (Fig. S3, Tables S3 and S4 in ESI†). About
44% of total identified proteins (147/333) are present only in
CTRL, while about 22% are detected only in RCC UE (72/333),
suggesting the occurrence of a diﬀerential protein content in the
two groups (Tables 2 and 3). About 75% of identified proteins is
present also in Exocarta – an updated database reporting all the
identified exosome molecules – in the section regarding UE.31
However, it is worth noting that a good percentage of identified
proteins (about 25%) is not yet reported in Exocarta (Fig. 6).
The cellular localizations of the identified proteins (Fig. 7A),
based on UniProtKB, an Expasy resource, indicate that the
majority of them are in the plasma membrane, in vesicle-
related organelles (e.g. cytoplasmic and membrane bound
vesicles, early and late endosomes, lysosomes, secretory gran-
ules, and ER-Golgi intermediate compartment), and in the
cytoskeleton. Moreover, in the RCC exosome pool, a high
percentage (35%) is represented by secreted proteins, while it
is reduced (only 15%) in CTRL ones.
The identified proteins were also analysed from a functional
point of view (Fig. 7B), and we assessed the presence of many
typical exosomal proteins, such as the component of the
ESCRT machinery (TSG101), proteins involved in traﬃcking
Table 3 (continued )
Name Accession (UNIPROT) MW (Da) Mascot score Localization
Immune response
Annexin A3 P12429 36 524 35 Secreted
Complement C3 P01024 188 569 231 Secreted
Complement C4-A P0C0L4 194 247 52 Secreted
Complement component C9 P02748 64 615 32 Plasmamembrane
Endothelial protein C receptor Q9UNN8 26 997 66 Plasmamembrane
Ig g-3 chain C region P01860 42 287 89 Secreted
Ig heavy chain V-III region TIL P01765 12 462 85 Secreted
Ig heavy chain V-III region VH26 P01764 12 745 54 Secreted
Ig k chain V-III region SIE P01620 11 882 100 Secreted
Ig k chain V-III region VG (Fragment) P04433 12 681 38 Secreted
Ig k chain V-IV region (Fragment) P06312 13 486 49 Secreted
Ig k chain V-IV region Len P01625 12 746 39 Secreted
Ig l chain V-III region LOI P80748 12 042 33 Secreted
Inter-a-trypsin inhibitor heavy chain H4 Q14624 103 521 132 Secreted
Monocyte diﬀerentiation antigen CD14 P08571 40 678 30 Plasmamembrane
Peptidoglycan recognition protein 1 O75594 22 116 73 Secreted
Serpin B3 P29508 44 594 103 Cytoplasm
TIR domain-containing adapter molecule 1 Q8IUC6 77 343 17 Plasmamembrane
a1-Antitrypsin P01009 46 878 354 Secreted
Others/unknown
a-2-Macroglobulin P01023 164 613 226 Secreted
Antithrombin-III P01008 53 025 41 Secreted
Cathepsin P07339 45 037 35 Organelles
Deoxyribonuclease-1 P24855 31 642 86 Secreted
Eukaryotic translation initiation factor 6 P56537 27 095 35 Cytoplasm
Fibrinogen b chain P02675 56 577 36 Secreted
Fibrinogen g chain P02679 52 106 31 Secreted
Ganglioside GM2 activator P17900 21 281 51 Organelles
Haptoglobin P00738 45 861 34 Secreted
Heat shock-related 70 kDa protein 2 P54652 70 263 56 Other/unknown
Hemopexin P02790 52 385 24 Secreted
Integrator complex subunit 4-like protein 1 Q96LV5 49 382 24 Other/unknown
Leucine-rich a-2-glycoprotein P02750 38 382 72 Secreted
Multimerin-2 Q9H8L6 105 028 38 Secreted
Protein archease Q8IWT0 19 535 35 Other/unknown
Ras-related protein Rab-5A P20339 23 872 23 Plasmamembrane
Retinoid-inducible serine carboxypeptidase Q9HB40 51 083 48 Secreted
Serum amyloid P-component P02743 25 485 37 Secreted
Transmembrane protein 44 Q2T9K0 53 061 21 Plasmamembrane
Fig. 6 Venn diagram showing the overlapping and the unique proteins identi-
fied in CTRL and RCC UE with that reported in Exocarta UE.
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and membrane fusion (annexins), and tetraspanins such as CD9,
possibly correlated to the exosome biogenesis mechanism.30
Moreover, many other functional classes were recognized, such
as metabolic enzymes (i.e. triosophosphate isomerase, isocitrate
dehydrogenase), proteins involved in signalling (i.e. Ras-related
proteins), related to cellular adhesion and motility (i.e. ezrin,
syntenin 1), communication (G-proteins), and transport
(i.e. chloride intracellular channel protein 1 CLIC1). The presence
of these proteins highlights the UE cellular origin. A consistent
diﬀerence between the two pools concerns the percentage of
immunity related proteins. In fact they are 18% for RCC and
7% for control exosomes. Although it must be considered that
each protein is counted once in this classification, regardless of its
absolute content, this result may be related to the activation of the
immune system encountered in neoplastic diseases, and to one of
the putative functions of exosomes, which is immune system
regulation. Furthermore, many species in this group belong to the
immunoglobulin family, providing a possible explanation for the
above reported increase of secreted proteins in tumour exosomes.
Despite the well-known involvement of angiogenesis in RCC,
only a few proteins related to this function were found in our
proteomic analysis of urinary exosomes. A possible explanation
for this finding is that the tumour cells may retain such
strategic molecules, or release them towards the internal micro-
environment;32 on the other hand, it has to be underlined that
our analytical condition did not allow for the identification of
low abundant UE proteins. Moreover, the fact that urinary
exosomes are not a preferred vehicle for these kinds of mole-
cules is also suggested by their under-representation in an
extensive list of UE proteins recently published.33
When we compared the enrichment of the biological func-
tions on the same scale (by Ingenuity Pathway Analysis
resource), the analysis showed that the profile of biological
functions associated with RCC UE proteins diﬀers considerably
from CTRL ones (Fig. 8). In fact, the species related to cell
death, scavenger of free radicals and cellular movement are
more enriched in pathological UE, while molecular transport
class is enriched in controls.
Western blot
To further validate the diﬀerential proteomic profiles of UE
from RCC patients compared to controls, we examined some
Fig. 7 Bioinformatic analysis of UE proteins. (A) Subcellular localization; (B) molecular functions.
Fig. 8 Top biological functions of proteins identified in RCC and CTRL UE. The significance of the enrichment is expressed as the log (p value).
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Fig. 9 Validation of diﬀerential RCC and Ctrl UE protein content by western blotting. (A) 4 representative cases are shown. (B) Densitometric quantification of bands
after normalization by creatinine values. * = p o 0.05, ** = p o 0.005, *** = p o 0.0001.
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protein levels in UE. Protein selection was based on several
criteria including (1) our previous results obtained by gene and
protein expression profiling on RCC tissue samples;26,34
(2) their potential roles in contributing to RCC diagnosis, and
(3) the availability of commercial antibodies. Based on the
above criteria, we selected a panel of 10 proteins, and subjected
their UE diﬀerential content to validation using western blot
analysis (Fig. 9A). After densitometric quantification of band
intensity, results were expressed as DO per mg of creatinine in
Fig. 9B. Results show that Matrix metalloproteinase 9 (MMP-9),
Ceruloplasmin (CP), Podocalyxin (PODXL), Dickkopf related
protein 4 (DKK4) and Carbonic Anhydrase IX (CAIX) are signifi-
cantly more abundant in RCC patient UE, while Aquaporin-1
(AQP1), Extracellular Matrix Metalloproteinase Inducer (EMMPRIN),
Neprilysin (CD10), Dipeptidase 1 and Syntenin-1 display a
significant reduced content in RCC patient’s UE.
MMP9, DKK4 and EMMPRIN are involved in extracellular
matrix remodeling.35–37 Moreover, it has been reported that
these three proteins are overexpressed in RCC and correlate
with RCC aggressiveness and high RCC metastatic potential by
promoting tumor cell migration and invasion.26,36,38,39 Accord-
ingly, the MMP9 and DKK4 increased content in RCC UE could
be correlated to these features. This hypothesis is supported by
a recent paper showing that exosomes derived from gynecologic
neoplasias contain metalloproteinases that increase extra-
cellular matrix degradation and augment tumor invasion into
the stroma.36 In contrast, EMMPRIN could be retained by
tumor cells, because of its capability to induce the activation
of the extracellular matrix metalloproteases such as MMP9,
thus explaining its reduced content in RCC urinary exosomes,
compared to control ones.
PODXL and AQP1 are typical proteins expressed by human
kidney: PODXL is highly expressed in podocytes and is impor-
tant for the maintenance of the cellular morphology and the
anti-adhesive properties of these cells,40 while AQP1 is a
membrane water channel physiologically expressed by the
proximal tubule and the loop of Henle. AQP1 (both mRNA and
protein) was reported to be downregulated in RCC tissues.41,42
Its reduction may be related to the loss of cellular specialization,
a sort of ‘‘dediﬀerentiation’’ strategy; this could explain also its
decreased content in UE. PODXL, in contrast, has recently
emerged as a malignant marker in tumors arising from a variety
of tissues, including also RCC.43 Syntenin-1, in contrast to
PODXL, is reported to be involved in the cellular adhesion by
coupling the syndecan-2 to the cytoskeleton.44 It is expressed,
among other tissues, also in the kidney, and is a typical exosomal
protein.31
DPEP1 is important for the physiological activity of renal
cells, in particular in glutathione metabolism; for this reason it
may be eliminated in urinary exosomes by tumour cells as
another possible strategy to promote tumor development and
progression, due to the reduction of the free radical detoxifica-
tion power.45 Neprilysin (CD10) is normally expressed by the
proximal tubules and by the glomerular epithelial cells: it is a
zinc-dependent metallopeptidase, which is involved in the
metabolism of a number of regulatory peptides and plays an
important role in turning oﬀ peptide signalling at the cell
surface.46 Loss or decrease in neprilysin expression has been
reported inmany types ofmalignancies, including renal cancer.34,47
DPEP1 and CD10 demonstrate to have a reduced content in
RCC UE, compared to control ones, possibly according to the
loss of the cellular specialization, as already mentioned.
Finally, the levels of CAIX and CP are found significantly
increased in RCC urinary exosomes: it has to be underlined that
their promoters were reported to be activated by the transcrip-
tional factor HIF-1a, known to be involved in RCC genesis.48–50
In particular, gene expression profiling on renal tissue showed
a marked CP mRNA overexpression in RCC patients compared
to controls,34,51 while CAIX is proven to be a powerful tissue
marker for ccRCC and was recently shown to correlate with
tumor size.52 Both CP and CAIX have been detected in RCC
patient serum.52,53
Summarizing, protein profiling and validation results indi-
cate that the pattern of RCC UE resembles that of cancer tissue
for some proteins, but it displays quite distinctive and specific
features overall. As such, our data indicate that the RCC
patient’s UE protein profile significantly diﬀers from that of
control subjects (Fig. 10). It has to be underlined that also the
RCC UE lipid composition was recently demonstrated to be
diﬀerential,54 providing further evidence for a relationship
between UE composition and RCC disease.
Western blot results were then used to generate ROC curves,
to predict the potential impact for use of the biomarker
candidates in discriminating between the RCC group and the
controls; the AUC values were determined for each protein and
range between 0.73–1. In particular, CP and PODXL resulted to
have AUC equal to 1, suggesting to be best at distinguishing
RCC patients from the control group. The ROC curves and the
AUC values of the other 8 proteins are shown in Fig. 11. Thus,
these results could constitute a basis for the set-up of a multi-
marker strategy in UE for RCC detection. This approach would
guarantee a more valid diagnostic result compared to the single
markers, because less dependent upon the inter-individual
diﬀerences, typical of polygenic diseases. In fact, although CP
seems to have the best diagnostic performance, in AUC terms,
Fig. 10 Radar plot comparing the diﬀerent levels of selected proteins (derived
from Fig. 9A and B) in RCC and CTRL UE.
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it has been suggested that its increase in RCC serum could be
part of an acute phase response to the cancer as an unspecific
marker of inflammation.53 Moreover, it is likely that the use of
multiple markers will assure a better specificity towards clear
cell RCC, than the single one: the assessment of this hypothesis
deserves further investigation.
Finally, in order to get a more comprehensive portrait of
diﬀerential RCC protein abundance in exosomes, an appealing
solution is represented by a protein microarray format along
with western blot. It could give sensitive, real-time and multi-
plexed detection on a targeted set of specific proteins, and
would allow us to validate a panel of discriminating proteins.
Then the protein microarray could be easily used for diagnosis
or post-surgery monitoring of RCC. We intend to evaluate this
approach in a future work.
Concluding remarks
To the best of our knowledge, this is the first proteomic study
performed on urinary exosomes obtained from RCC patients.
Taken together, the present results show that (1) due to their
biochemical and morphological characteristics, vesicles iso-
lated by ultracentrifugation from urine samples collected from
patients and controls are enriched in ‘‘bona fide’’ exosomes;
(2) UE proteome represents a peculiar and readily isolated subset
of the urinary proteome, and is enriched in cell-derived proteins,
which may possibly be involved in the RCC pathogenesis or
progression; (3) RCC UE protein content is substantially and
reproducibly diﬀerent from the control UE one.
In conclusion, our work suggests that exosome isolation may
provide an eﬃcient first step in RCC biomarker discovery in urine.
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